Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Condition(s):Ductal Breast Carcinoma In Situ; HER2/Neu PositiveLast Updated:April 20, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Ductal Breast Carcinoma In Situ; HER2/Neu PositiveLast Updated:April 20, 2018Completed
Condition(s):Breast CancerLast Updated:May 17, 2017Completed
Condition(s):Ductal Breast Carcinoma in Situ; Estrogen Receptor-positive Breast CancerLast Updated:July 21, 2015Completed
Condition(s):Ductal Breast Carcinoma In SituLast Updated:October 26, 2020Active, not recruiting
Condition(s):Breast NeoplasmsLast Updated:March 17, 2015Recruiting
Condition(s):Atypical Ductal Breast Hyperplasia; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in SituLast Updated:January 11, 2021Recruiting
Condition(s):Ductal Breast Carcinoma in SituLast Updated:February 6, 2020Recruiting
Condition(s):Ductal Breast Carcinoma In SituLast Updated:September 4, 2020Recruiting
Condition(s):Breast CancerLast Updated:March 29, 2010Completed
Condition(s):Breast Cancer in SituLast Updated:April 23, 2018Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.